Esperion Therapeutics (ESPR) Retained Earnings (2012 - 2026)

Esperion Therapeutics has reported Retained Earnings for 15 years, with the latest figure at -$1.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings changed 0.45% year-over-year to -$1.6 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.6 billion (changed 0.45% YoY), and the FY2025 full-year result was -$1.6 billion, changed N/A from the prior year.
• Retained Earnings for Q1 2026 stood at -$1.6 billion, down from -$1.6 billion in the prior quarter.
• The five-year high for Retained Earnings was -$1000.0 in Q1 2023, with the low at -$1.7 billion in Q3 2025.
• Historically, Retained Earnings has averaged -$1.2 billion across 5 years, with a median of -$1.5 billion in 2023.
• Annual changes were most pronounced in 2023 — Retained Earnings surged 100.0% — and 2024, when it plunged 148826100.0%.
• Esperion Therapeutics' Retained Earnings stood at -$2000.0 in 2022, then tumbled by 77464100.0% to -$1.5 billion in 2023, then decreased by 1.96% to -$1.6 billion in 2024, then slipped by 2.79% to -$1.6 billion in 2025, then fell by 1.55% to -$1.6 billion in 2026.
• The last three Retained Earnings figures came in at -$1.6 billion (Q1 2026), -$1.6 billion (Q4 2025), and -$1.7 billion (Q3 2025), per Business Quant data.